A Study of BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
AXIOMATIC-SSP: A Study of BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
Lead PI: Prof Graeme Hankey
No. of Patients Currently Recruited: 165 No. of Patients Required: 2350
AXIOMATIC-SSP is a Phase 2, Randomised, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Convert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack. This trial aims to determine the safety and efficacy of adding different doses on an oral factor Xia inhibitor to dual antiplatelet therapy with aspirin and clopidogrel in 2350 patients with acute (<48 hours) minor ischaemic stroke or TIA.